Rohit Parehk
Direttore/Membro del Consiglio presso Cora Therapeutics, Inc.
Profilo
Rohit Parehk currently works as a Director at Cora Therapeutics, Inc.
Posizioni attive di Rohit Parehk
Società | Posizione | Inizio |
---|---|---|
Cora Therapeutics, Inc.
Cora Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cora Therapeutics, Inc. is a data-driven health solutions company based in Toronto, CA. The product is clinically proven and patented to minimize the irreversible damage to DNA caused by radiation from medical imaging such as CT and X-ray, and cosmic radiation on planes at high altitudes. The Canadian company, under the leadership of Dr. Kieran Murphy, a renowned interventional neuroradiologist, is committed to minimizing the collateral damage caused by radiation exposure. The team is complemented by the esteemed scientific advisor, Dr. Mark Tarnopolsky, who is a frontrunner in evaluating and developing nutraceutical treatments for disorders associated with oxidative stress. The company's first product, Halo antioxidant, is launching in 2022. The company's formulations are developed using the wealth of knowledge possessed by their team and validated through clinical research. The company was founded by Kieran Murphy, and the CEO is David Simpson. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Cora Therapeutics, Inc.
Cora Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cora Therapeutics, Inc. is a data-driven health solutions company based in Toronto, CA. The product is clinically proven and patented to minimize the irreversible damage to DNA caused by radiation from medical imaging such as CT and X-ray, and cosmic radiation on planes at high altitudes. The Canadian company, under the leadership of Dr. Kieran Murphy, a renowned interventional neuroradiologist, is committed to minimizing the collateral damage caused by radiation exposure. The team is complemented by the esteemed scientific advisor, Dr. Mark Tarnopolsky, who is a frontrunner in evaluating and developing nutraceutical treatments for disorders associated with oxidative stress. The company's first product, Halo antioxidant, is launching in 2022. The company's formulations are developed using the wealth of knowledge possessed by their team and validated through clinical research. The company was founded by Kieran Murphy, and the CEO is David Simpson. | Commercial Services |
- Borsa valori
- Insiders
- Rohit Parehk